Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2020-10-22
Target enrollment:
Participant gender:
Summary
Background:
- Hodgkins lymphoma (HL) is a highly treatable cancer. However, if HL does not respond to
chemotherapy or returns after chemotherapy, further treatments often are not successful.
- Some HL cells have a molecule called cluster of differentiation 25 (CD25) on the
surface. Daclizumab is a drug that can detect CD25 on cells. In a treatment study for HL
that did not respond to chemotherapy, daclizumab plus a radioactive atom called Yttrium
90 helped kill these HL cells. Researchers want to combine this 90Y daclizumab with
high-dose chemotherapy and stem cell transplant. This treatment may be more effective
than the daclizumab alone.
Objectives:
- To see if yttrium-90 daclizumab, high-dose chemotherapy, and stem cell transplants can
treat HL that has not responded to earlier treatments.
Eligibility:
- Individuals at least 18 years of age who have Hodgkins lymphoma that has not responded to
chemotherapy.
Design:
- Participants will be screened with a physical exam and medical history. They will also
have blood and urine tests.
- Participants will have filgrastim and plerixafor to move stem cells into the blood. Stem
cells will be collected with apheresis.
- Four weeks after stem cells are collected, participants will have the 90Y daclizumab and
normal daclizumab to treat the HL. Chemotherapy will start 9 days after the first
treatment.
- Most participants will have a second dose of 90Y daclizumab 6 weeks after the first
dose.
- After each daclizumab treatment, participants will have several imaging studies of the
chest and abdomen. Blood samples will also be collected.
- On the day after the last day of chemotherapy, participants will receive the stem cells
collected earlier. Filgrastim injections will help stimulate stem cell growth....